Search This Blog

Tuesday, September 15, 2026

RBC upgrades ResMed to Outperform from Sector Perform, raises price target to $262 from $244

 


  • RBC cites continued benefits from growing global obstructive sleep apnea awareness and penetration for ResMed's long-term growth.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)